 ENGLEWOOD, CO ACCESSWIRE June 3, 2020 Aytu BioScience, Inc. AYTU the Company, a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that, as of July 1, 2020, Express Scripts, Inc., Express Scripts, one of the leading pharmacy benefit managers PBMs in the United States, has elected to make Natesto testosterone nasal gel a preferred brand on its National Preferred Drug List. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, This improved formulary placement by Express Scripts is a significant development for Natesto enabling greater patient access in the U.S. The addition of Natesto as Preferred on the Express Scripts National Preferred formulary will enable significantly increased access to Natesto for the 13 million U.S. men diagnosed with hypogonadism. 